# Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

> **NCT05620160** · PHASE3 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 1359 (actual)

## Conditions studied

- Mild to Moderate COVID-19

## Interventions

- **DRUG:** RAY1216
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05620160
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-12
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-03-28
- **Target enrollment:** 1359 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05620160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05620160, "Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05620160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*